174 related articles for article (PubMed ID: 28440407)
21. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
Shih PS; Huang JD
Drug Metab Dispos; 2002 Dec; 30(12):1491-6. PubMed ID: 12433824
[TBL] [Abstract][Full Text] [Related]
22. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
Galettis P; Boutagy J; Ma DD
Br J Cancer; 1994 Aug; 70(2):324-9. PubMed ID: 7914424
[TBL] [Abstract][Full Text] [Related]
23. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
24. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
[TBL] [Abstract][Full Text] [Related]
25. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
26. CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome.
Silveira VS; Canalle R; Scrideli CA; Queiroz RG; Lopes LF; Tone LG
Mol Cell Biochem; 2012 May; 364(1-2):217-23. PubMed ID: 22215203
[TBL] [Abstract][Full Text] [Related]
27. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
Kishi S; Yang W; Boureau B; Morand S; Das S; Chen P; Cook EH; Rosner GL; Schuetz E; Pui CH; Relling MV
Blood; 2004 Jan; 103(1):67-72. PubMed ID: 12969965
[TBL] [Abstract][Full Text] [Related]
28. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.
Zhou X; Gao YY; Hu JY; Dong Y; Zhang HZ; Lai Y
Eur J Clin Pharmacol; 2018 Jan; 74(1):37-44. PubMed ID: 28986606
[TBL] [Abstract][Full Text] [Related]
29. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
30. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia.
Lopes BA; Emerenciano M; Gonçalves BA; Vieira TM; Rossini A; Pombo-de-Oliveira MS
PLoS One; 2015; 10(5):e0127308. PubMed ID: 25992585
[TBL] [Abstract][Full Text] [Related]
32. Polymorphism analysis of CYP3A5 in myeloid leukemia.
Liu TC; Lin SF; Chen TP; Chang JG
Oncol Rep; 2002; 9(2):327-9. PubMed ID: 11836601
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between the CYP3A5 genetic polymorphism and susceptibility to and prognosis of childhood acute leukemia].
Huang Z; Chai YH; Cen JN
Zhonghua Er Ke Za Zhi; 2007 Jul; 45(7):546-8. PubMed ID: 17953817
[No Abstract] [Full Text] [Related]
34. [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia].
Sun YN; Chai YH; Xu YJ; Lü H
Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):296-300. PubMed ID: 19555570
[TBL] [Abstract][Full Text] [Related]
35. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
36. The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children.
Abo El Fotoh WM; Abd El Naby SA; Habib MS; ALrefai AA; Kasemy ZA
Seizure; 2016 Oct; 41():75-80. PubMed ID: 27498208
[TBL] [Abstract][Full Text] [Related]
37. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.
Nakkam N; Tiamkao S; Kanjanawart S; Tiamkao S; Vannaprasaht S; Tassaneeyakul W; Tassaneeyakul W
Drug Metab Pharmacokinet; 2015 Aug; 30(4):295-304. PubMed ID: 26099919
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
39. Genotyping cytochrome P450 3A5 using the Light Cycler.
Fredericks S; Moreton M; MacPhee IA; Mohamed M; Marlowe S; Jorga A; Johnston A; Carter ND; Holt DW
Ann Clin Biochem; 2005 Sep; 42(Pt 5):376-81. PubMed ID: 16168193
[TBL] [Abstract][Full Text] [Related]
40. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
